{"id":63722,"date":"2026-04-22T21:24:36","date_gmt":"2026-04-22T13:24:36","guid":{"rendered":"https:\/\/flcube.com\/?p=63722"},"modified":"2026-04-22T21:24:36","modified_gmt":"2026-04-22T13:24:36","slug":"roches-gazyva-gains-fda-review-acceptance-for-systemic-lupus-erythematosus-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63722","title":{"rendered":"Roche’s Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment"},"content":{"rendered":"\n

Roche AG<\/strong> (SWX: ROP<\/a>, OTCMKTS: RHHBY<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has accepted for review its market filing for Gazyva\/Gazyvaro (obinutuzumab)<\/strong> as a treatment for systemic lupus erythematosus (SLE)<\/strong>, with a decision expected by December 2026<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone & Clinical Evidence<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Trial Name<\/strong><\/td>Phase III ALLEGORY study<\/td><\/tr>
Primary Endpoint<\/strong><\/td>SLE Response Index 4 (SRI-4) at 52 weeks<\/td><\/tr>
Endpoint Met<\/strong><\/td>Yes \u2013 with statistical and clinical significance<\/td><\/tr>
SRI-4 Definition<\/strong><\/td>Composite measure of disease severity reduction, symptom improvement, and physical status stabilization<\/td><\/tr>
Current Approvals<\/strong><\/td>Approved in 100 countries for hematologic malignancies; approved in U.S. and EU for lupus nephritis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The filing builds on Gazyva’s established profile in lupus nephritis, potentially expanding its indication to the broader SLE patient population.<\/p>\n\n\n\n

Drug Mechanism & Differentiation<\/h2>\n\n\n\n